ECDC MISSION REPORT 19–21 September 2016 ; 14–15 November 2016
Miscellaneous
Child and adolescent psychiatric emergencies
Chapter J.1
HIV drug resistance , Users Manual
December 2017
Supplement to the 2016 consolidated Guidelines on the use of antiretroviral drugs for Treating and Preventing HIV infection
HIV Treatment
We as a large world community are facing an extraordinary challenge: keeping healthy against the threat of rapidly spreading novel Covid-19 virus. Starting with flu-like symptoms, the virus attacks the airways leading to severe breathing difficulties in the m ost vulnerable, that is, those whose im ...m unity is decreased because of various reasons: age over 65, living with chronic illness, taking im m unity reducing medicines. Rapid spread of the virus along with severity of its sym ptom s led health specialists to recommend social distancing, confinement and thorough hand washing to our governm ents who took actions to implement these guidelines.
more
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...n 2018 on diagnosing, preventing, and managing cryptococcal disease. In response to important new evidence that became available in 2021, these new guidelines strongly recommend a single high dose of liposomal amphotericin B as part of the preferred induction regimen for the treatment of cryptococcal meningitis in people living with HIV. This simplified regimen - a single high dose of liposomal amphotericin B paired with other standard medicines (flucytosine and fluconazole) - is as effective as the previous WHO standard of care, with the benefits of lower toxicity and fewer monitoring demands.
The objective of these guidelines is to provide updated, evidence-informed recommendations for treating adults, adolescents and children living with HIV who have cryptococcal disease. These guidelines are aimed at HIV programme managers, policymakers, national treatment advisory boards, implementing partners and health-care professionals providing care for people living with HIV in resource-limited settings with a high burden of cryptococcal disease.
more
These guidelines – an update to the World Health Organization’s 2015 publication Consolidated strategic information guidelines – present a set of essential aggregate indicators and guidance on choosing, collecting and systematically analysing strategic information to manage and monitor the nat...ional health sector response to HIV.
more
Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...duce mortality. The purpose of the meeting was to
Review the current research and implementation data on the use of prophylactic antibiotics (specifically azithromycin/macrolides) as part of the AHD package of care; To review options for preventing SBIs that are in line with goals of reducing AMR; Present the current evidence on diagnostics for SBI; Discuss research gaps and implementation challenges.
more
The survey highlights changes that have taken place in Bangladesh’s demographic and health situation since the previous BDHS surveys. The survey provides important information for policymakers and program personnel in addressing the monitoring and evaluation needs of the 4th Health, Population and... Nutrition Sector Program (4th HPNSP) of the Ministry of Health Family Welfare (MOHFW).
more
Global HIV Strategic Information Working Group
March 2018, Vol. 108, (3 Suppl 1)